Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-046096
Filing Date
2025-03-27
Accepted
2025-03-27 16:19:53
Documents
88
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ikt-20241231.htm   iXBRL 10-K 2687177
2 EX-2.1 ikt-ex2_1.htm EX-2.1 901303
3 EX-10.27 ikt-ex10_27.htm EX-10.27 58549
4 EX-10.28 ikt-ex10_28.htm EX-10.28 367711
5 EX-10.29 ikt-ex10_29.htm EX-10.29 358225
6 EX-10.30 ikt-ex10_30.htm EX-10.30 44179
7 EX-19.1 ikt-ex19_1.htm EX-19.1 122902
8 EX-21.1 ikt-ex21_1.htm EX-21.1 7311
9 EX-23.1 ikt-ex23_1.htm EX-23.1 11179
10 EX-31.1 ikt-ex31_1.htm EX-31.1 16122
11 EX-31.2 ikt-ex31_2.htm EX-31.2 16194
12 EX-32.1 ikt-ex32_1.htm EX-32.1 10213
13 EX-32.2 ikt-ex32_2.htm EX-32.2 10230
  Complete submission text file 0000950170-25-046096.txt   12102954

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ikt-20241231.xsd EX-101.SCH 1416734
90 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20241231_htm.xml XML 1508023
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39676 | Film No.: 25779570
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)